




Forward-looking Statements

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995:


This presentation may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to future events or DLH's future financial performance. Any statements that refer to expectations, projections or other characterizations of future events or circumstances or that are not statements of historical fact (including without limitation statements to the effect that the Company or its management "believes", "expects", "anticipates", "plans", "intends" and similar expressions) should be considered forward looking statements that involve risks and uncertainties which could cause actual events or DLH's actual results to differ materially from those indicated by the forward-looking statements. Forward-looking statements in this presentation include, among others, statements regarding benefits of the acquisition, estimates of future revenues, operating income, earnings, earnings per share, backlog, and cash flows. These statements reflect our belief and assumptions as to future events that may not prove to be accurate. Our actual results may differ materially from such forward-looking statements made in this presentation due to a variety of factors, including: the risk that we will not realize the anticipated benefits of the acquisition of SSS; the diversion of management's attention from normal daily operations of the business and the challenges of managing larger and more widespread operations resulting from the acquisition; the inability to retain SSS employees and customers; contract awards in connection with re-competes for present business and/or competition for new business; compliance with new bank financial and other covenants; the risks and uncertainties associated with client interest in and purchases of new services; changes in client budgetary priorities; government contract procurement (such as bid protest, small business set asides, loss of work due to organizational conflicts of interest, etc.) and termination risks; the ability to successfully integrate the operations of SSS and any future acquisitions; and other risks described in our SEC filings. For a discussion of such risks and uncertainties which could cause actual results to differ from those contained in the forward-looking statements, see "Risk Factors" in the Company's periodic reports filed with the SEC, including our Annual Report on Form 10-K for the fiscal year ended September 30, 2018, as well as interim quarterly filings thereafter. The forward-looking statements contained herein are not historical facts, but rather are based on current expectations, estimates, assumptions and projections about our industry and business. Such forward-looking statements are made as of the date hereof and may become outdated over time. The Company does not assume any responsibility for updating forward-looking statements, except as may be required by law.



Management Presentation Team











Business Overview

Overview

Founded 1969

Headquarters: Atlanta, GA



Complementary Offices: **▼** Silver Spring, MD



1986

- > 1,900 Skilled employees
- Located in > 30 Locations in the US and overseas

Technology Enabled Services and Solutions

Healthcare Research



Disease Prevention



Program Monitoring & Evaluation



Patient Care Services



3 Market Focus Areas



Defense and Veterans Solutions



Human Services & Solutions



Public Health & Life Sciences



Mission Driven and Customer Focused



















SSS Acquisition Rationale

Highly complementary businesses with common core capabilities for complex, nationally dispersed programs, operational synergies, and new business opportunities



Accelerates long-term strategy of both entities – public health & life sciences capabilities with a proven secure data analytics platform to go to market




Reduces portfolio risk especially in view of Kingdomware (set-aside) impact on legacy VA revenue and profit delivery; adds > \$300M unfunded contract backlog



Government contract consolidations (and IDIQ focus), coupled with industry mergers, place greater value on scale for small, mid-tier organic competitiveness



Market Portfolio Balanced via SSS Addition



DOD & Veteran Health Services Market

Pro Forma Annual Revenue: ~\$90M

Key Capabilities: Mail-order pharmacy ops, virtual pharmacy, behavioral health, substance abuse counseling, training, disability assessments, care coordination,

case management

Recent Customers: VHA, Navy, BUMED, DHA, USAMMA

Human Services & Solutions Market

Pro Forma Annual Revenue: ~\$40M

Key Capabilities: Large-scale program monitoring & evaluation, data collection and management, trend analyses, congressional reporting, electronic medical records

migration, nutritional and social health assessments

Recent Customers: ACF OHS, DHS, USAID

Public Health & Life Sciences Market

Pro Forma Annual Revenue: ~\$70M


Key Capabilities: Disease prevention and health promotion, clinical trials, epidemiology studies, environmental studies, public health policy data analysis, microsimulation, statistical data analysis and national reporting, website & social media campaigns, biological research and surveys, capacity-building

Recent Customers: CDC, NIH, CMS, AHRQ, DOI

2019 DLH Holdings Corp - Confidential and Proprietary



Looking Ahead











SSS Service Areas













Strategic Differentiator







Acquisition – Financial Benefits


- Purchase price represents a multiple of ~11x on EBITDA
- Highly visible revenue
 - Acquired company has approx. \$345 million of total backlog, of which \$40 million is funded
 - Due to research and studies nature of work, contract durations tend to be longer
- Expected strong free cash flow and debt service
 - Free cash flow is supported by tax-deductible purchase price and prior DLH tax shield
 - Capital requirements of the business are minimal
- Substantial existing contract base
 - The acquired company's contract portfolio supports 100% of its expected FY19 revenue and 95% of expected FY20 revenue
- Significant potential for combined organic growth
 - Revenue growth driven primarily by continued execution against recurring customer requirements, cross-selling opportunities (expanding offerings into each other's respective markets), and unsaturated customer bases





Track Record of Success

Historical Revenue (\$ in millions)




Historical EBITDA* (\$ in millions)




*A reconciliation of net income to EBITDA is provided in the appendix to this presentation.


FY2019 Q3 Financial Results











Revenue:

Revenue increase reflects program timing and acquisition of SSS

Gross Profit:

25.6% in FY19Q3 versus 23.1% in FY18Q3

Operating Income:

Operating income was impacted by \$1.2 million of acquisitionrelated transaction expenses in the quarter

EBITDA:

As a percent of revenue, EBITDA was 6.7% in FY19Q3 vs 8.9% in FY18Q3 principally due to acquisition-related transaction expenses incurred in the quarter

2019 DLH Holdings Corp. - Confidential and Proprietary

16



Balance Sheet Highlights

- Cash on hand of \$6.0 million as of June 30, 2019
- \$70 million of new senior debt represents a leverage level of 3.47x proforma LTM Adjusted EBITDA⁽¹⁾ at closing
- Focus on debt pay-down with \$6.5 million of voluntary debt payments since June 7 \$3.9 million on June 30 and \$2.6 million on July 31

First Na	ational Bank Group	First National Bank Group					
Term Loan	\$70 million	Revolving Line of Credit	\$25 million (none drawn at close)				
Interest Rate	LIBOR +4.0% ⁽²⁾	Interest Rate	LIBOR +4.0% ⁽²⁾				
Term	5.0 years	Maturity	5.0 years				

Please note that additional financing terms are discussed in detail in Form 8-K filed with SEC

⁽¹⁾ Adjusted EBITDA pursuant to definition provided in new senior loan agreement, which adds non-cash stock expense and transaction expense to EBITDA.

²⁾ Interest rate spread ranges from 2.5% - 4.5%, depending on the total leverage ratio.



Our Levers of Value Creation

- Revenue Stream Growth
 - Focus on Federal agencies with sustained bipartisan support
 - Optimize workforce and service delivery

- Sustainable Margin Expansion
 - Concentrate on capture of professional work projects that typically yield higher gross margins
 - Pursue excellence across key dimensions of agility and cost efficiency

- S Long-Term Cash Flow Growth
 - Expand EBITDA and balance sheet optimization
- Drive working capital efficiency and free cash flow

- Balanced
 Capital
 Deployment
- Push growth organically and through M&A
- Balance debt and equity financing







Appendix: Non-GAAP Reconciliations

This document contains non-GAAP financial information. Management uses this information in its internal analysis of results and believes this information may be informative to investors in gauging the quality of our financial performance, identifying trends in our results, and providing meaningful period-to-period comparisons. These measures should be used in conjunction with, rather than instead of, their comparable GAAP measures. A reconciliation of non-GAAP measures to the comparable GAAP measures presented in this document also is contained in the company's most recent earnings press release.



Trending EBITDA Reconciliation

Twelve Months Ended September 30,

Amounts in \$000s	2013	2014	2015	2016	2017	2018	LTM
Net (loss)/income	\$ (159)	\$ 5,357	\$ 8,728	\$ 3,384	\$ 3,288	\$ 1,836	\$ 5,515
(i) Interest expense/other (income)	407	4	(744)	823	1,228	1,116	1,599
(ii) (Benefit)/provision for taxes	_	(4,597)	(5,488)	(938)	2,114	5,830	2,279
(iii) Depreciation and amortization	121	106	55	1,244	1,754	2,242	2,625
EBITDA	\$ 369	\$ 870	\$ 2,551	\$ 4,513	\$ 8,384	\$ 11,024	\$ 12,018



FY19 Q3 EBITDA Reconciliation

Three Months Ended

Nine Months Ended

			June 30,	June 30,					
Amounts in \$000s	2019		2018	Change	2019	2018	Change		
Net income	\$	803 \$	1,614 \$	(811)	3,758 \$	79 \$	3,679		
(i) Interest expense		562	262	300	1,284	801	483		
(ii) Provision for taxes		325	738	(413)	1,532	5,084	(3,552)		
(iii) Depreciation and amortization		914	588	326	2,037	1,654	383		
EBITDA	\$	2,604 \$	3,202 \$	(598)	8,611 \$	7,618 \$	993		

